Table 1.
Plasma Lipids, HDL Parameters, CEC, Anti-Inflammatory Function, and Antioxidant Function During Hypothyroidism and During TH Supplementation in 17 Patients with Differentiated Thyroid Carcinoma
| Parameter | Hypothyroidism | Thyroid Hormone Supplementation | P Value |
|---|---|---|---|
| Total cholesterol (mg/dL) | 248.0 (216.5, 288.5) | 152.0 (140, 167.5) | <0.001 |
| Non-HDL cholesterol (mg/dL) | 180.0 (148.5, 218.0) | 99.0 (83.0, 109.5) | <0.001 |
| LDL cholesterol (mg/dL) | 138.0 (120.5, 169.5) | 79 (64.5, 92.0) | <0.001 |
| HDL cholesterol (mg/dL) | 68.0 (57.5, 85.5) | 57.0 (45.0, 66.0) | 0.001 |
| Triglyceride (mg/dL) | 130.0 (99.5, 175.0) | 83.0 (73.5, 116.0) | <0.001 |
| ApoA-1 (mg/dL) | 156.0 (136.0, 181.0) | 144.0 (133.0, 161.0) | 0.007 |
| Total HDLP (µmol/L) | 23.3 (21.4, 25.5) | 23.2 (21.7, 24.8) | 0.948 |
| Large HDLP (µmol/L) | 4.2 (2.6, 6.4) | 1.0 (1.6 ,2.9) | <0.001 |
| Medium HDLP (µmol/L) | 5.1 (3.3, 5.5) | 6.6 (5.5, 8.8) | <0.001 |
| Small HDLP (µmol/L) | 14.4 (13.3, 15.9) | 13.2 (12.3, 16.3) | 0.463 |
| H7P (µmol/L) | 1.0 (0.5, 1.5) | 0.5 (0.2, 0.8) | 0.001 |
| H6P (µmol/L) | 2.1 (0.8, 4.1) | 0.6 (0.3, 1.2) | 0.001 |
| H5P (µmol/L) | 0.8 (0.2, 1.0) | 0.4 (0.2, 0.8) | 0.255 |
| H4P (µmol/L) | 1.1 (0.9, 1.7) | 2.3 (1.3, 3.3) | 0.008 |
| H3P (µmol/L) | 3.2 (2.3, 4.5) | 5.6 (3.1, 6.3) | 0.002 |
| H2P (µmol/L) | 11.1 (8.8, 12.4) | 10.8 (8.7, 12.7) | 0.554 |
| H1P (µmol/L) | 3.2 (3.1, 5.1) | 3.3 (1.8, 5.1) | 0.079 |
| HDL size (nm) | 9.6 (9.2, 9.9) | 9.0 (9.3, 9.8) | <0.001 |
| CEC (AU) | 0.90 (0.83, 1.01) | 1.01 (0.93, 1.13) | 0.035 |
| Anti-oxidative capacity (%) | 60.1 (58.3, 63.1) | 61.6 (58.6, 64.1) | 0.332 |
Data in median (interquartile range). Statistical comparisons were done by paired samples Wilcoxon signed-rank tests. Significant changes are indicated in bold.
Abbreviations: ApoA-1, apolipoprotein A-1; CEC: cholesterol efflux capacity; HDL, high-density lipoproteins; HDLP, HDL particles; H7P to H1P, larger to smaller HDL particles (see Methods); LDL, low-density lipoproteins.